Orphazyme was founded in Denmark in 2009 on a scientific discovery about the role of heat shock proteins (HSPs), which was described in a well-cited article published in the journal Nature.
We translated this scientific discovery into late-stage clinical trials of our investigational drug candidate, arimoclomol, with the aim of developing new treatment options for people with neurodegenerative diseases, such as Niemann-Pick disease type-C (NPC).
At 2017 the company was listed at Nasdaq Copenhagen and in May 2022 the company sold all assets and business activities, including those relating to the development and approval of arimoclomol to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc.
In May 2023 a new board took was selected at the general assembly starting the proces of finding af new activity for the company.
The company is owed by approximately 12.000 shareholders.